Goldman Sachs Group, Inc. (The) Analysts Give MorphoSys AG (MOR) a €72.00 Price Target
Goldman Sachs Group, Inc. (The) set a €72.00 ($85.71) price objective on MorphoSys AG (ETR:MOR) in a research report sent to investors on Thursday. The firm currently has a neutral rating on the stock.
Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. set a €62.00 ($73.81) price target on MorphoSys AG and gave the company a neutral rating in a research report on Friday, August 4th. Berenberg Bank set a €68.00 ($80.95) price target on MorphoSys AG and gave the company a buy rating in a research report on Wednesday, August 16th. Deutsche Bank AG set a €90.00 ($107.14) price target on MorphoSys AG and gave the company a buy rating in a research report on Thursday, September 7th. Independent Research GmbH set a €77.00 ($91.67) price target on MorphoSys AG and gave the company a buy rating in a research report on Thursday, September 7th. Finally, Commerzbank Ag set a €76.00 ($90.48) price target on MorphoSys AG and gave the company a buy rating in a research report on Monday, July 24th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average target price of €73.13 ($87.05).
Shares of MorphoSys AG (ETR MOR) opened at 71.20 on Thursday. The firm has a 50-day moving average price of €60.74 and a 200-day moving average price of €59.75. The company’s market capitalization is €2.06 billion. MorphoSys AG has a one year low of €35.72 and a one year high of €72.59.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Stock Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related stocks with our FREE daily email newsletter.